Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nortriptyline for smoking cessation: a review.

John R Hughes1, Lindsay F Stead, Tim Lancaster

  • 1Departments of Psychiatry, Psychology, and Family Practice, University of Vermont, Burlington, VT 05401, USA. john.hughes@uvm.edu

Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco
|August 9, 2005
PubMed
Summary

Nortriptyline, an antidepressant, effectively doubles smoking cessation quit rates. While generally safe, its use as a second-line treatment is recommended until more data on side effects in healthy individuals is available.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel abuse liability assessment of e-cigarettes in young adults ii: Reinforcement enhancement and follow-up assessment.

Experimental and clinical psychopharmacology·2023
Same author

Potential effects of nicotine content in cigarettes on use of other substances.

Preventive medicine·2022
Same author

The interactive effects of JUUL flavor and nicotine concentration on addiction potential.

Experimental and clinical psychopharmacology·2022
Same author

A systematic review and meta-analysis of interventions to induce attempts to quit tobacco among adults not ready to quit.

Experimental and clinical psychopharmacology·2022
Same author

Subsuming general practice into acute NHS services is a red herring.

BMJ (Clinical research ed.)·2022
Same author

Cumulative vulnerabilities as a potential moderator of response to reduced nicotine content cigarettes.

Preventive medicine·2021

Area of Science:

  • Pharmacology
  • Addiction Medicine
  • Clinical Trials

Background:

  • Smoking cessation remains a significant public health challenge.
  • Pharmacological interventions are crucial for aiding smokers to quit.
  • Nortriptyline, a tricyclic antidepressant, has shown potential in smoking cessation.

Purpose of the Study:

  • To review the efficacy of nortriptyline for smoking cessation.
  • To compare nortriptyline's effectiveness with other cessation aids.
  • To assess the safety profile of nortriptyline in smoking cessation.

Main Methods:

  • Meta-analysis of placebo-controlled trials from the Cochrane Library.
  • Inclusion of six relevant clinical trials.
  • Analysis of quit rates and adverse events.

Related Experiment Videos

Main Results:

  • Nortriptyline (75-100 mg) demonstrated a significant increase in quit rates, doubling success rates (OR = 2.1).
  • Adverse events led to dropout in 4-12% of participants, with no serious events reported.
  • Efficacy did not correlate with antidepressant properties, suggesting other mechanisms.

Conclusions:

  • Nortriptyline is an effective aid for smoking cessation, comparable to bupropion and nicotine replacement therapies.
  • Its efficacy may be linked to dopaminergic or adrenergic activity, not serotonergic.
  • Recommended as a second-line treatment due to limited data on serious side effects in healthy smokers.